A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis.

Trial Profile

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Quilizumab (Primary) ; Quilizumab (Primary)
  • Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
    • 04 Jan 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top